Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples

References

• Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas Iii CF, Rader C. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 2003; 325:325-35; PMID:12488098; http://dx.doi.org/10.1016/S0022-2836(02)01232-9
   PubMed Web of Science ®Google Scholar
• Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci USA 1995; 92:9348-52; PMID:7568130; http://dx.doi.org/10.1073/pnas.92.20.9348
   PubMed Web of Science ®Google Scholar
• Cheung WC, Beausoleil SA, Zhang X, Sato S, Schieferl SM, Wieler JS, Beaudet JG, Ramenani RK, Popova L, Comb MJ, et al. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat Biotechnol 2012; 30:447-52; PMID:22446692; http://dx.doi.org/10.1038/nbt.2167
   PubMed Web of Science ®Google Scholar
• Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, Cohen LS, Welt S, Old LJ, Barbas CF. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 2000; 275:13668-76; PMID:10788485; http://dx.doi.org/10.1074/jbc.275.18.13668
   PubMed Web of Science ®Google Scholar
• Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F, Dei Tos AP. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 2005; 124:295-302; PMID:16040303; http://dx.doi.org/10.1309/NR8HN08GDPVEMU08
   PubMed Web of Science ®Google Scholar
• Zhang Y-F, Phung Y, Gao W, Kawa S, Hassan R, Pastan I, Ho M. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma. Sci Rep 2015; 5:9928; PMID:25996440; http://dx.doi.org/10.1038/srep09928
   PubMed Web of Science ®Google Scholar
• Bendell JC, Fakih M, Infante JR, Bajor DL, Cristea MC, Tremblay T, Trifan OC, Vonderheide RH. Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors. ASCO annual meeting; J Clin Oncol 2016; 34 (suppl; abstr TPS3110); http://meetinglibrary.asco.org/content/164672-176
   Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge R. The immunogenicity of humanized and fully human antibodies. mAbs 2010; 2:256-65; PMID:20400861; http://dx.doi.org/10.4161/mabs.2.3.11641
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5; PMID:3713831; http://dx.doi.org/10.1038/321522a0
   PubMed Web of Science ®Google Scholar
• Verhoeyen M, Milstein C, Winter G. Reshaping human antibodies: grafting an antilysozyme activity. Science 1988; 239:1534-6; PMID:2451287; http://dx.doi.org/10.1126/science.2451287
   PubMed Web of Science ®Google Scholar
• Williams D, Matthews D, Jones T. Humanising antibodies by CDR grafting. In: Kontermann R, Dübel S, eds. Springer Berlin Heidelberg: Antibody Engineering, 2010:319-39; http://dx.doi.org/10.1007/978-3-642-01144-3_21
   Google Scholar
• Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989; 86:10029-33; PMID:2513570; http://dx.doi.org/10.1073/pnas.86.24.10029
   PubMed Web of Science ®Google Scholar
• Kashmiri SVS, De Pascalis R, Gonzales NR, Schlom J. SDR grafting—a new approach to antibody humanization. Methods 2005; 36:25-34; PMID:15848072; http://dx.doi.org/10.1016/j.ymeth.2005.01.003
   PubMed Web of Science ®Google Scholar
• Rader C, Cheresh DA, Barbas CF. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci USA 1998; 95:8910-5; PMID:9671778; http://dx.doi.org/10.1073/pnas.95.15.8910
   PubMed Web of Science ®Google Scholar
• Jones T, Crompton L, Carr F, Baker M. Deimmunization of monoclonal antibodies. In: Dimitrov AS, ed. Therapeutic Antibodies: Humana Press, 2009:405-23; PMID:19252848; http://dx.doi.org/10.1007/978-1-59745-554-1_21
   Google Scholar
• Alard P, Desmet J, Lasters I. In silico de-immunization. In: Kontermann R, Dübel S, eds. Springer Berlin Heidelberg: Antibody Engineering, 2010:369-76; http://dx.doi.org/10.1007/978-3-642-01144-3_24
   Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13:869-78; PMID:22884505; http://dx.doi.org/10.1016/S1470-2045(12)70329-7
   PubMed Web of Science ®Google Scholar
• Jackisch C, Kim S-B, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol 2015; 26:320-5; PMID:25403587; http://dx.doi.org/10.1093/annonc/mdu524
   PubMed Web of Science ®Google Scholar
• Yu Y, Lee P, Ke Y, Zhang Y, Yu Q, Lee J, Li M, Song J, Chen J, Dai J, et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One 2010; 5:e9072; PMID:20140208; http://dx.doi.org/10.1371/journal.pone.0009072
   PubMed Web of Science ®Google Scholar
• Lavinder JJ, Hoi KH, Reddy ST, Wine Y, Georgiou G. Systematic characterization and comparative analysis of the rabbit immunoglobulin repertoire. PLoS One 2014; 9:e101322; PMID:24978027; http://dx.doi.org/10.1371/journal.pone.0101322
   PubMedGoogle Scholar
• Knight KL, Becker RS. Molecular basis of the allelic inheritance of rabbit immunoglobulin VH allotypes: Implications for the generation of antibody diversity. Cell 1990; 60:963-70; PMID:2317867; http://dx.doi.org/10.1016/0092-8674(90)90344-E
   PubMed Web of Science ®Google Scholar
• Mage R. Rabbit immune system. In: Vohr H-W, ed. Encyclopedic Reference of Immunot: Springer Berlin Heidelberg, 2005:545-9; http://dx.doi.org/10.1007/3-540-27806-0_1248
   Google Scholar
• Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970; 132:211-50; PMID:5508247; http://dx.doi.org/10.1084/jem.132.2.211
   PubMed Web of Science ®Google Scholar
• Kabat EA, Te Wu T, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. Diane Publ Company, 1992; ISBN: 9780941375658.
   Google Scholar
• Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196:901-17; PMID:3681981; http://dx.doi.org/10.1016/0022-2836(87)90412-8
   PubMed Web of Science ®Google Scholar
• Lefranc M-P, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 2003; 27:55-77; PMID:12477501; http://dx.doi.org/10.1016/S0145-305X(02)00039-3
   PubMed Web of Science ®Google Scholar
• Padlan EA, Abergel C, Tipper JP. Identification of specificity-determining residues in antibodies. FASEB J 1995; 9:133-9. PMID:7821752.
   PubMed Web of Science ®Google Scholar
• Kunik V, Peters B, Ofran Y. Structural consensus among antibodies defines the antigen binding site. PLoS Comput Biol 2012; 8:e1002388; PMID:22383868; http://dx.doi.org/10.1371/journal.pcbi.1002388
   PubMed Web of Science ®Google Scholar
• Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol 2013; 4:302; PMID:24115948; http://dx.doi.org/10.3389/fimmu.2013.00302
   PubMed Web of Science ®Google Scholar
• Tramontano A, Chothia C, Lesk AM. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol 1990; 215:175-82; PMID:2118959; http://dx.doi.org/10.1016/S0022-2836(05)80102-0
   PubMed Web of Science ®Google Scholar
• Xiang J, Sha Y, Jia Z, Prasad L, Delbaere LTJ. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. J Mol Biol 1995; 253:385-90; PMID:7473721; http://dx.doi.org/10.1006/jmbi.1995.0560
   PubMed Web of Science ®Google Scholar
• Borras L, Gunde T, Tietz J, Bauer U, Hulmann-Cottier V, Grimshaw JPA, Urech DM. Generic approach for the generation of stable humanized single-chain fv fragments from rabbit monoclonal antibodies. J Biol Chem 2010; 285:9054-66; PMID:20056614; http://dx.doi.org/10.1074/jbc.M109.072876
   PubMed Web of Science ®Google Scholar
• Pastan I, Ho M. Recombinant immunotoxins for treating cancer. In: Kontermann R, Dubel S, eds. Antibody Engineering. Berlin-Heidelberg: Springer-Verlag, 2010:127-46; http://dx.doi.org/10.1007/978-3-642-01147-4
   Google Scholar
• Haidar JN, Yuan Q-A, Zeng L, Snavely M, Luna X, Zhang H, Zhu W, Ludwig DL, Zhu Z. A universal combinatorial design of antibody framework to graft distinct CDR sequences: A bioinformatics approach. Proteins: Struct Funct Bioinform 2012; 80:896-912; PMID:22180101; http://dx.doi.org/10.1002/prot.23246
   PubMed Web of Science ®Google Scholar
• Raghunathan G, Smart J, Williams J, Almagro JC. Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J Mol Recognit 2012; 25:103-13; PMID:22407974; http://dx.doi.org/10.1002/jmr.2158
   PubMed Web of Science ®Google Scholar
• MacCallum RM, Martin ACR, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 1996; 262:732-45; PMID:8876650; http://dx.doi.org/10.1006/jmbi.1996.0548
   PubMed Web of Science ®Google Scholar
• Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RGE, Hötzel I, Popplewell AG, Parren PWHI, Enzelberger M, Rademaker HJ, et al. The INNs and outs of antibody nonproprietary names. mAbs 2016; 8:1-9; PMID:26716992; http://dx.doi.org/10.1080/19420862.2015.1114320
   PubMed Web of Science ®Google Scholar
• Roque-Navarro L, Mateo C, Lombardero J, Mustelier G, Fernández A, Sosa K, Morrison SL, Pérez R. Humanization of predicted T-Cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003; 22:245-57; PMID:14511570; http://dx.doi.org/10.1089/153685903322328974
   PubMedGoogle Scholar
• Stickler M, Chin R, Faravashi N, Gebel W, Razo OJ, Rochanayon N, Power S, Valdes AM, Holmes S, Harding FA. Human population-based identification of CD4+ T-cell peptide epitope determinants. J Immunol Methods 2003; 281:95-108; PMID:14580884; http://dx.doi.org/10.1016/S0022-1759(03)00279-5
   PubMed Web of Science ®Google Scholar
• Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46-53; PMID:17945478; http://dx.doi.org/10.1016/j.ejca.2007.08.028
   PubMed Web of Science ®Google Scholar
• Hassan R, Thomas A, Alewine C, Le D, Jaffee E, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 2016; 34:4171-9. PMID:27863199; http://dx.doi.org/10.1200/JCO.2016.68.3672
   PubMed Web of Science ®Google Scholar
• Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009; 284:3739-49; PMID:19075018; http://dx.doi.org/10.1074/jbc.M806776200
   PubMed Web of Science ®Google Scholar
• Ho M, Hassan R, Zhang J, Wang Q-c, Onda M, Bera T, Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005; 11:3814-20; PMID:15897581; http://dx.doi.org/10.1158/1078-0432.CCR-04-2304
   PubMed Web of Science ®Google Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011; 67:235-42; PMID:21460441; http://dx.doi.org/10.1107/S0907444910045749
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-12; PMID:15264254; http://dx.doi.org/10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008; 9:1-8; PMID:18173834; http://dx.doi.org/10.1093/bib/bbn041
   PubMed Web of Science ®Google Scholar
• DiMattia MA, Watts NR, Stahl SJ, Rader C, Wingfield PT, Stuart DI, Steven AC, Grimes JM. Implications of the HIV-1 Rev dimer structure at 3.2 Å resolution for multimeric binding to the Rev response element. Proc Natl Acad Sci USA 2010; 107:5810-4; PMID:20231488; http://dx.doi.org/10.1073/pnas.0914946107
   PubMed Web of Science ®Google Scholar
• Stahl SJ, Watts NR, Rader C, Dimattia MA, Mage RG, Palmer I, Kaufman JD, Grimes JM, Stuart DI, Steven AC, et al. Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev. J Mol Biol 2010; 397:697-708; PMID:20138059; http://dx.doi.org/10.1016/j.jmb.2010.01.061
   PubMed Web of Science ®Google Scholar
• Lammens A, Baehner M, Kohnert U, Niewoehner J, von Proff L, Schraeml M, Lammens K, Hopfner K-P. Crystal structure of human TWEAK in complex with the fab fragment of a neutralizing antibody reveals insights into receptor binding. PLoS One 2013; 8:e62697; PMID:23667509; http://dx.doi.org/10.1371/journal.pone.0062697
   PubMedGoogle Scholar
• Pan R, Sampson JM, Chen Y, Vaine M, Wang S, Lu S, Kong X-P. Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans. J Virol 2013; 87:10221-31; PMID:23864637; http://dx.doi.org/10.1128/JVI.00843-13
   PubMed Web of Science ®Google Scholar
• Malia TJ, Teplyakov A, Brezski RJ, Luo J, Kinder M, Sweet RW, Almagro JC, Jordan RE, Gilliland GL. Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge. Proteins: Struct Funct Bioinform 2014; 82:1656-67; PMID:24638881; http://dx.doi.org/10.1002/prot.24545
   PubMed Web of Science ®Google Scholar